OnKure Therapeutics, Inc.
OKUR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.12 | 0.02 | -0.00 |
| FCF Yield | -35.11% | -41.15% | -24.29% | -18.36% |
| EV / EBITDA | 2.24 | 3.31 | 2.26 | -0.16 |
| Quality | ||||
| ROIC | -23.08% | -20.66% | -18.55% | -32.21% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.86 | 0.88 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 1.84% | 5.25% | 33.43% | -97.26% |
| Safety | ||||
| Net Debt / EBITDA | 4.81 | 5.44 | 5.70 | 3.52 |
| Interest Coverage | -7,750.50 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |